onc Videos

Videos

Kathleen Moore, MD, Stephenson Cancer Center

Videos

Mirvetuximab Soravtansine Improved Overall Survival for Patients With Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer

07/27/2023

At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.

At the 2023 ASCO Annual Meeting,...

07/27/2023

Oncology

Videos

Epcoritamab Plus Rituximab and Lenalidomide Regimen Demonstrates High Response Rates Among Patients With High-Risk Follicular Lymphoma

07/19/2023

Reid Merryman , MD;

At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.

At the 2023 ASCO meeting, Reid...

07/19/2023

Oncology

Eileen O'Reilly, MD, Memorial Sloan Kettering Cancer Center

Videos

Current Standards and Emerging Options for Pancreatic Cancer

07/18/2023

Eileen M. O'Reilly , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.

At the 2023 World Congress on...

07/18/2023

Oncology

Videos

Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer

07/18/2023

Tsz Lun Yeung , MD;

At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.

At the 2023 ASCO Annual Meeting,...

07/18/2023

Oncology

Paul Paik, MD, Memorial Sloan Kettering Cancer Center

Videos

Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer

07/17/2023

Paul K. Paik , MD;

At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Ticiana Leal, MD, Winship Cancer Institute

Videos

Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer

07/17/2023

Ticiana Leal , MD;

At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Videos

Targeting KRAS in Gastrointestinal Cancers

07/14/2023

At the 2023 World Congress on Gastrointestinal Cancers, John Strickler, MD, reviews the currently available and upcoming strategies in targeting KRAS in gastrointestinal cancers.

At the 2023 World Congress on...

07/14/2023

Oncology

Van Morris, MD, MD Anderson Cancer Center

Videos

Ipilimumab Added to Nivolumab Does Not Significantly Improve Survival Outcomes for Patients With Squamous Cell Carcinoma of the Anal Canal

07/13/2023

Van Morris , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Van Morris, MD, presented results from a phase 2 study evaluating the addition of ipilimumab to nivolumab for patients with previously treated, unresectable or metastatic squamous cell...

At the 2023 World Congress on...

07/13/2023

Oncology

Rachel Purcell, PhD, University of Otago, Christchurch

Videos

Effect of Microbiome on Colorectal Cancer Tumor Microenvironment

07/13/2023

Rachel Purcell , PhD;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, different microbes in the colorectal cancer tumor microenvironment were found to increase immune activity and potentially have an immunosuppressive effect.

According to a study presented...

07/13/2023

Oncology

Michael White, MD, MD Anderson Cancer Center

Videos

Mutational Signature Similarities and Differences Between Appendiceal Adenocarcinoma and Colorectal Cancer

07/13/2023

Michael White , MD;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, there were distinct mutational differences noted between appendiceal adenocarcinoma and colorectal cancer.

According to a study presented...

07/13/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology